| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2014-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2020-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102182485-B1 |
| titleOfInvention |
Antibody locker for the inactivation of protein drug |
| abstract |
Described herein are hinge antibodies that can be selectively activated in a target cell or tissue to treat a disease of the target cell or tissue. The hinge antibody comprises a functional antibody, two inhibitory domains and four cleavable linkers. Functional antibodies can treat disease in an activated state and have two light chains and two heavy chains. Each inhibitory domain contains the hinge domain of an immunoglobulin and is composed of two peptide arms. Each cleavable linker comprises a peptide substrate cleavable by an enzyme that is specifically or highly expressed in a target cell or tissue, and one of the peptide arms of the inhibitory domain is attached to the N-terminus of one of the light and heavy chains of the functional antibody. Connect. In addition, methods of making and using such hinge antibodies are described herein. |
| priorityDate |
2013-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |